Jour George, Andeen Nicole K, Al-Rohil Rami, Aung Phyu P, Mehrotra Meenakshi, Duose Dzifa, Hoch Benjamin, Argenyi Zolt, Luthra Rajyalakshmi, Wistuba Ignacio I, Prieto Victor G
Department of Pathology and Laboratory Medicine, MD Anderson Cancer Center at Cooper, One Cooper Plaza, Camden, NJ, USA.
Department of Pathology, University of Washington School of Medicine, 1959 NE Pacific Street, Seattle, WA, USA.
J Pathol. 2018 Jan;244(1):97-106. doi: 10.1002/path.4996.
Superficial malignant peripheral nerve sheath tumour (MPNST) is a rare, soft tissue neoplasm that shares morphological features and some molecular events with spindle/desmoplastic melanoma (SDM). Herein, we sought to identify molecular targets for therapy by using targeted RNA/DNA sequencing and gene expression of key immunological players. DNA and RNA from formalin-fixed paraffin-embedded tissue were extracted and processed. Massive high-throughput deep parallel sequencing was performed with the Oncomine comprehensive panel, enabling detection of relevant single-nucleotide variants, copy number variations, gene fusions and indels for 143 unique genes on the Ion torrent sequencer for clinical trial research programmes. Gene expression analysis was carried out with a customized 770-gene expression panel combining markers for 24 different immune cell types and 30 common cancer antigens, including key checkpoint blockade genes analysed with the Ncounter system. Fifty-one patients (SDM, 16/11; MPNST, 24; male, n = 37; female, n = 16) had sufficient DNA and RNA for testing. NF1 deleterious mutations and/or deep/homozygous deletions were identified in 73% of MPNSTs and 67% of SDMs, with 50% of the mutations involving the RAS-binding domain. Inactivating/deleterious mutations of TSC1/TSC2 were identified in 40% and 41% of MPNSTs and SDMs, respectively. Activating mutations affecting the EGFR-like and the negative regulatory domains of NOTCH1 and KDR (VEGFR2) were identified in 45% and 40% of SDMs and in 30% and 8% of MPNSTs, respectively. Differential gene expression and gene clustering analysis showed significantly perturbed immune pathway components, including nuclear factor-κB (NF-κB), JAK-STAT, and CXCL12-CXCR4, and differentially expressed CD274 and CTLA4, in both SDM and MPNST. Angiogenesis (KDR and NOTCH1) and mammalian target of rapamycin complex (mTORC) pathways offer a rationale for anti-angiogenic and selective mTORC inhibition as treatment strategies for MPNST and SDM. Cytokines and the JAK-STAT, TNF and NF-κB axes were perturbed in both SDM and MPNST. These pathways have been targeted in haematological malignancies and present promising targets for these tumours. Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
浅表性恶性外周神经鞘瘤(MPNST)是一种罕见的软组织肿瘤,与梭形/促纤维增生性黑色素瘤(SDM)具有形态学特征和一些分子事件。在此,我们试图通过使用靶向RNA/DNA测序和关键免疫参与者的基因表达来确定治疗的分子靶点。从福尔马林固定石蜡包埋组织中提取并处理DNA和RNA。使用Oncomine综合检测板进行大规模高通量深度平行测序,能够在Ion torrent测序仪上检测143个独特基因的相关单核苷酸变异、拷贝数变异、基因融合和插入缺失,用于临床试验研究项目。使用定制的770基因表达检测板进行基因表达分析,该检测板结合了24种不同免疫细胞类型和30种常见癌症抗原的标志物,包括用Ncounter系统分析的关键检查点阻断基因。51名患者(SDM,16/11;MPNST,24;男性,n = 37;女性,n = 16)有足够的DNA和RNA用于检测。在73%的MPNST和67%的SDM中鉴定出NF1有害突变和/或深度/纯合缺失,其中50%的突变涉及RAS结合域。分别在40%的MPNST和41%的SDM中鉴定出TSC1/TSC2的失活/有害突变。在45%的SDM和30%的MPNST中分别鉴定出影响EGFR样以及NOTCH1和KDR(VEGFR2)负调控域的激活突变,在40%的SDM和8%的MPNST中分别鉴定出影响EGFR样以及NOTCH1和KDR(VEGFR2)负调控域的激活突变。差异基因表达和基因聚类分析显示,在SDM和MPNST中,免疫途径成分(包括核因子-κB(NF-κB)、JAK-STAT和CXCL12-CXCR4)以及差异表达的CD274和CTLA4均受到显著干扰。血管生成(KDR和NOTCH1)和雷帕霉素复合物哺乳动物靶点(mTORC)途径为抗血管生成和选择性mTORC抑制作为MPNST和SDM的治疗策略提供了理论依据。细胞因子以及JAK-STAT、TNF和NF-κB轴在SDM和MPNST中均受到干扰。这些途径已在血液系统恶性肿瘤中作为靶点,并且是这些肿瘤有前景的靶点。版权所有©2017英国和爱尔兰病理学会。由John Wiley & Sons, Ltd.出版。